section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp

Migration, Crosslink

📖

section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-242-advanced-s

📖 Wiki Page

therapeutic1201 wordssynced 2026-04-02

Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Type</td>
</tr>
<tr>
<td class="label">Bemdaneprocel</td>
<td>hESC-DA</td>
</tr>
<tr>
<td class="label">STEM-PD</td>
<td>hESC-DA</td>
</tr>
<tr>
<td class="label">Kyoto iPSC-DA</td>
<td>iPSC-DA</td>
</tr>
<tr>
<td class="label">MSC trials (various)</td>
<td>MSC</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical feasibility</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">CBS/PSP specificity</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Evidence strength</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Overall</td>
<td>35/60</td>
</tr>
</table>

Introduction

...

Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Type</td>
</tr>
<tr>
<td class="label">Bemdaneprocel</td>
<td>hESC-DA</td>
</tr>
<tr>
<td class="label">STEM-PD</td>
<td>hESC-DA</td>
</tr>
<tr>
<td class="label">Kyoto iPSC-DA</td>
<td>iPSC-DA</td>
</tr>
<tr>
<td class="label">MSC trials (various)</td>
<td>MSC</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical feasibility</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">CBS/PSP specificity</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Evidence strength</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Overall</td>
<td>35/60</td>
</tr>
</table>

Introduction

Mermaid diagram (expand to render)

Stem cell therapy represents one of the most transformative approaches in neurodegenerative disease treatment, offering the potential for actual neuronal replacement rather than merely slowing degeneration. For corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), cell-based therapies aim to replace lost dopaminergic and other affected neurons, modulate the immune environment, and provide trophic support to endogenous neurons.

Unlike Parkinson's disease, where dopaminergic neuron loss is relatively focal, CBS and PSP involve more widespread neurodegeneration affecting cortical, basal ganglia, brainstem, and spinal cord regions. This creates both challenges and opportunities for cell therapy approaches.

Rationale for Cell Therapy in CBS/PSP

The pathological features of CBS and PSP that make cell therapy a compelling approach include:

Selective neuronal loss: Specific populations (dopaminergic neurons in substantia nigra, cortical neurons, brainstem nuclei) are preferentially affected, making targeted replacement feasible

Non-cell-autonomous factors: Neuroinflammation and gliosis contribute to disease progression—MSC-based immunomodulation can address these

Trophic factor deficiency: Endogenous neurotrophin production is impaired—cells can provide paracrine support

4R-tau pathology: Unlike 3R+4R tau in AD, 4R-tau in CBS/PSP may respond differently to cellular interventions

Stem Cell Types for CBS/PSP

Induced Pluripotent Stem Cell (iPSC)-Derived Dopamine Neurons

Patient-derived iPSCs can be differentiated into midbrain dopamine neurons:

Advantages: Autologous (patient-matched), reduced immune rejection, personalized disease modeling
Challenges: Manufacturing time (3-6 months), cost, regulatory hurdles
Clinical status: Phase I/II trials in Parkinson's disease (Kyoto University, Nature 2025) showing 44.7% increase in putaminal dopamine
CBS/PSP relevance: iPSC-derived neurons can model 4R-tau pathology, test patient-specific drug responses, and potentially be transplanted

Human Embryonic Stem Cell (hESC)-Derived Dopamine Progenitors

Bemdaneprocel (BlueRock Therapeutics)

Cell type: hESC-derived midbrain dopamine progenitors
Delivery: Stereotactic transplantation to putamen
Phase: Phase III registrational trial active
Results: Phase I/II showed 21.9-point UPDRS improvement vs baseline
CBS/PSP considerations: Would require modified protocols for 4R-tau environments, potentially combined with anti-tau approaches

STEM-PD (Lund University/Cambridge)

Cell type: hESC-derived dopamine neurons
Phase: Phase I/IIa ongoing
Results: 100,000-200,000 surviving dopamine neurons observed post-transplantation
CBS/PSP considerations: Safety data from this trial will inform CBS/PSP applications

Mesenchymal Stem Cells (MSCs)

MSCs provide neuroprotection through paracrine mechanisms:

Sources: Bone marrow, umbilical cord, adipose tissue
Delivery routes: Intravenous, intrathecal, intracerebral
Mechanisms: Immunomodulation, trophic factor secretion (BDNF, GDNF, VEGF), anti-inflammatory effects
Clinical trials: Safety established in PD, ALS; multiple trials active
CBS/PSP relevance: Particularly valuable given prominent neuroinflammation in these disorders

Neural Stem Cells (NSCs)

Endogenous or derived NSCs offer multi-lineage potential:

Potential: Replace multiple neurotransmitter systems (dopaminergic, GABAergic, glutamatergic)
Challenges: Limited expansion capacity, migration control
Clinical status: Early-stage; not yet in neurodegeneration trials

Clinical Trial Landscape for CBS/PSP

Neuronal Replacement Strategies

Striatal Dopamine Transplantation

The putamen is the primary target for dopamine neuron transplantation:

Rationale: Reinnervation of striatum can restore dopaminergic signaling
Challenges: Need for long-distance axon extension in tauopathic environment
Combined approaches: May require concurrent anti-tau therapy to protect grafts

Substantia Nigra Reconstruction

Targeting the source rather than the target:

Rationale: Restore the nigrostriatal pathway integrity
Challenges: More complex surgical targeting, longer regeneration time

Cortical Neuron Replacement

For CBS with prominent cortical involvement:

Target: Motor cortex, frontal cortex
Cell types: Cortical neuron progenitors, NSC-derived neurons
Challenges: Cortical circuit integration, appropriate synaptic targeting

Immunological Considerations

Allogeneic vs Autologous Approaches

Allogeneic (Donor-derived)

Off-the-shelf availability
Requires immunosuppression (tacrolimus, mycophenolate)
Risk of rejection, infection from long-term immunosuppression
Established manufacturing processes

Autologous (iPSC-derived)

Patient-matched, reduced rejection risk
Complex manufacturing (3-6 months)
Higher cost per patient
Not yet in clinical trials for neurodegeneration

HLA Engineering

Emerging technologies to reduce immune rejection:

HLA knockout iPSC lines
HLA-E overexpression to evade NK cells
Compatibility with standard immunosuppression

Delivery Methods

Stereotactic Intracerebral Injection

Target: Putamen primarily; substantia nigra for circuit reconstruction
Technique: Multiple injection tracks for broad coverage
Pros: Direct delivery, high local cell concentration
Cons: Invasive, hemorrhage risk

Intravenous Administration

Target: Systemic, with CNS migration to sites of inflammation
Pros: Minimally invasive, repeat dosing possible
Cons: BBB limits CNS delivery, peripheral organ trapping

Intrathecal Administration

Target: CSF-exposed CNS surfaces
Pros: Bypasses BBB, broader distribution
Cons: Variable distribution, infection risk

NET Assessment

Drug Interactions with Current Regimen

Levodopa

No direct interaction with stem cell therapies
May continue standard levodopa regimen
Post-transplant: levodopa may be reduced as graft function emerges (monitor carefully)

Rasagiline (MAO-B inhibitor)

No direct interaction with stem cell transplantation
Continue preoperative regimen
Post-operative: monitor for interactions with immunosuppressants if added

Combined Regimen

No contraindications identified
Immunosuppression (if allogeneic cells) requires careful drug interaction review
Monitor liver function with tacrolimus

Patient-Specific Considerations

Eligibility Assessment

Disease stage: Earlier stages (1-2) may benefit more from cell replacement

Cognitive status: Significant cognitive impairment may affect post-surgical compliance

Motor phenotype: CBS with prominent parkinsonism may respond better than PSP with prominent axial symptoms

Comorbidities: Cardiovascular disease, cancer history affect eligibility

Risk-Benefit Analysis

Potential benefits:

Dopamine restoration (improved motor function)
Neurotrophic support (slowed progression)
Immunomodulation (reduced neuroinflammation)

Risks to consider:

Surgical complications (hemorrhage, infection)
Immunosuppression complications (infection, metabolic)
Graft failure or rejection
Potential for dyskinesias (observed in some PD trials)

Recommended Actions

Monitor clinical trials: Track bemdaneprocel Phase III results closely

Consider MSC therapy: Lower risk, immunomodulatory approach available in clinical settings

Consult with transplant centers: University of Lund, Cambridge, Kyoto have active programs

Document preferences: Advance care planning for if/when cell therapy becomes available

Cross-Links

[Stem Cell Therapy for Parkinsonism](/therapeutics/stem-cell-therapy-parkinsonism)
[iPSC Drug Screening CBS/PSP](/therapeutics/ipsc-neurons-drug-screening-cbs-psp)
[Gene Therapy](/therapeutics/gene-therapy)
[Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
[Section 217: Advanced Cell Therapy](/therapeutics/section-217-advanced-cell-therapy-regenerative-medicine-cbs-psp)

References

[Takahashi et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's Disease. Nature 2025](https://doi.org/10.1038/s41586-025-08700-0)

[BlueRock Therapeutics. Bemdaneprocel Phase III Trial Update. 2024](https://www.bluerocktx.com/bluerock-therapeutics-advances-investigational-cell-therapy-bemdaneprocel-for-treating-parkinsons-disease-to-registrational-phase-iii-clinical-trial/)

[Lund University. STEM-PD Clinical Trial Update. 2024](https://www.lunduniversity.lu.se/article/update-stem-pd-clinical-trial-stem-cell-based-transplant-parkinsons-disease)

[Stoker & Barker. Current status and future perspectives on stem cell-based therapies for Parkinson's Disease. J Clin Med. 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC9978267/)

[Chen et al. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024](https://link.springer.com/article/10.1186/s40001-024-01987-1)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Programmable Neuronal Circuit Repair via Epigenetic CRISPR](/hypothesis/h-9d22b570) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: NURR1, PITX3, neuronal identity transcription factors
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: Cell-type-specific essential genes
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5cc7c43623fa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

63

Outgoing

131

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp

Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP

Introduction

Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP

Introduction

Rationale for Cell Therapy in CBS/PSP

Stem Cell Types for CBS/PSP

Induced Pluripotent Stem Cell (iPSC)-Derived Dopamine Neurons

Human Embryonic Stem Cell (hESC)-Derived Dopamine Progenitors

Mesenchymal Stem Cells (MSCs)

Neural Stem Cells (NSCs)

Clinical Trial Landscape for CBS/PSP

Neuronal Replacement Strategies

Striatal Dopamine Transplantation

Substantia Nigra Reconstruction

Cortical Neuron Replacement

Immunological Considerations

Allogeneic vs Autologous Approaches

HLA Engineering

Delivery Methods

Stereotactic Intracerebral Injection

Intravenous Administration

Intrathecal Administration

NET Assessment

Drug Interactions with Current Regimen

Levodopa

Rasagiline (MAO-B inhibitor)

Combined Regimen

Patient-Specific Considerations

Eligibility Assessment

Risk-Benefit Analysis

Recommended Actions

Cross-Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

section-242-advanced-stem-cell-therapy-neuronal-replacement-cbs-psp

Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP

Introduction

Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP

Introduction

Rationale for Cell Therapy in CBS/PSP

Stem Cell Types for CBS/PSP

Induced Pluripotent Stem Cell (iPSC)-Derived Dopamine Neurons

Human Embryonic Stem Cell (hESC)-Derived Dopamine Progenitors

Mesenchymal Stem Cells (MSCs)

Neural Stem Cells (NSCs)

Clinical Trial Landscape for CBS/PSP

Neuronal Replacement Strategies

Striatal Dopamine Transplantation

Substantia Nigra Reconstruction

Cortical Neuron Replacement

Immunological Considerations

Allogeneic vs Autologous Approaches

HLA Engineering

Delivery Methods

Stereotactic Intracerebral Injection

Intravenous Administration

Intrathecal Administration

NET Assessment

Drug Interactions with Current Regimen

Levodopa

Rasagiline (MAO-B inhibitor)

Combined Regimen

Patient-Specific Considerations

Eligibility Assessment

Risk-Benefit Analysis

Recommended Actions

Cross-Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion